文献速递脊柱关节炎

真实世界中艾克司单抗与其他b/tsDMARDs治疗银屑病关节炎的12个月疗效与持续性比较

Comparative effectiveness and persistence of ixekizumab and other b/tsDMARDs in patients with PsA from a real-world setting: 12-month results from the PRO-SPIRIT study.
PubMed 文献 · RMD Open · 2026-02-02

PRO-SPIRIT观察性研究预设中期分析,纳入1192例起始艾克司单抗(IXE)或其他b/tsDMARDs的银屑病关节炎(PsA)患者,比较12个月疗效与持续性。IXE组cDAPSA缓解率18.8%,对比IL-12/23i与IL-23i合并组cDAPSA缓解OR 2.0(95%CI 1.2-6.0)、VLDA OR 2.5(1.1-13.6)、疼痛LSM -7.3(-13.2至-0.7),对比TNFi的BSA改善LSM -0.9(-1.4至-0.1);各组持续性相似。

要点

  • IXE组12个月cDAPSA缓解率18.8%,为各组最高。
  • 对比IL-12/23i与IL-23i合并组,IXE的cDAPSA缓解OR 2.0、VLDA OR 2.5、疼痛LSM -7.3。
  • 对比TNFi,IXE的BSA改善LSM -0.9;各组治疗持续性相似。

核心结论

  • IXE患者对比IL-12/23i与IL-23i合并组,cDAPSA缓解与VLDA的OR更高且疼痛下降更明显。
  • IXE患者对比TNFi,BSA改善更明显。
  • 所有b/tsDMARDs的治疗持续性相似,停药原因各异。

研究设计与样本

  • PRO-SPIRIT观察性研究预设中期分析,多国队列n=1192例起始IXE或其他b/tsDMARDs的PsA患者。
  • 采用频率模型平均法比较疗效,并对缺失数据多重插补。
  • 进行IXE与TNFi、SEC、JAKi及IL-12/23i与IL-23i合并组的两两比较。

主要发现

  • 第12个月IXE组cDAPSA与BSA改善,cDAPSA缓解(评分≤4)率18.8%为最高。
  • 对比IL-12/23i与IL-23i合并组,IXE的cDAPSA缓解OR 2.0(95%CI 1.2-6.0)、VLDA OR 2.5(1.1-13.6)。
  • 对比IL-12/23i与IL-23i合并组,IXE疼痛LSM -7.3(95%CI -13.2至-0.7)。
  • 对比TNFi,IXE的BSA改善LSM -0.9(95%CI -1.4至-0.1)。
  • IXE与SEC结果相似,多数SEC患者接受300 mg剂量。

关键数值与推荐

  • cDAPSA缓解定义为cDAPSA评分≤4。
  • IXE组12个月cDAPSA缓解率18.8%。
  • 对比IL-12/23i与IL-23i合并组,cDAPSA缓解OR 2.0(95%CI 1.2-6.0),VLDA OR 2.5(1.1-13.6)。
  • 对比IL-12/23i与IL-23i合并组,疼痛LSM -7.3(95%CI -13.2至-0.7)。
  • 对比TNFi,BSA改善LSM -0.9(95%CI -1.4至-0.1)。

临床怎么用

  • 对PsA患者选择b/tsDMARDs时,IXE在cDAPSA缓解、VLDA及疼痛改善方面可能优于IL-12/23i与IL-23i。
  • 对关注皮肤BSA改善的PsA患者,IXE可能优于TNFi。
  • 各b/tsDMARDs持续性相似,停药原因需个体化评估。

局限性

  • 为预设中期分析,非最终分析。
  • 缺失数据采用多重插补处理。
  • SEC多数患者接受300 mg剂量,可能影响与IXE的比较解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This prespecified interim analysis of the PRO-SPIRIT observational study compares the effectiveness and persistence of ixekizumab (IXE) with other biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) among patients with psoriatic arthritis (PsA) after 12 months of real-world treatment. METHODS: Data were collected from a multinational cohort (n=1192) initiating IXE or other b/tsDMARDs. Comparative effectiveness between IXE and other b/tsDMARDs was assessed using frequentist model averaging, with multiple imputation for missing data. Pairwise comparisons were performed between IXE and tumour necrosis factor inhibitors (TNFi), secukinumab (SEC), Janus kinase inhibitors and pooled interleukin (IL)-12/23i & IL-23i groups. RESULTS: At month 12, IXE-treated patients displayed improvement in clinical Disease Activity in PsA index (cDAPSA) and body surface area (BSA) and the highest remission rate (cDAPSA score≤4; 18.8%). Versus pooled IL-12/23i and IL-23i, IXE patients were more likely to achieve cDAPSA remission (OR 2.0 (95% CI 1.2 to 6.0)) or very low disease activity (VLDA; OR 2.5 (1.1 to 13.6)), with greater pain reduction (least squares mean (LSM) (95% CI) -7.3 (-13.2 to -0.7)). Compared with TNFi, IXE patients exhibited greater BSA improvement (LSM (95% CI) -0.9 (-1.4 to -0.1)). IXE and SEC results were similar; most SEC patients received the 300 mg dose. Persistence rates were similar across groups, with varying reasons for discontinuation. CONCLUSIONS: IXE patients had significantly greater odds of achieving cDAPSA remission and VLDA, plus greater pain reduction versus the pooled IL-12/23i and IL-23i group, with significant improvements in BSA versus TNFi. Treatment persistence was similar among all b/tsDMARDs.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Marzo-Ortega H, Sewerin P, Selmi C, et al. Comparative effectiveness and persistence of ixekizumab and other b/tsDMARDs in patients with PsA from a real-world setting: 12-month results from the PRO-SPIRIT study. RMD Open. 2026. PMID: 41629128. doi:10.1136/rmdopen-2025-006447

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。